Schedule‐dependent in vitro combination effects of methotrexate and 5‐fluorouracil in human tumor cell lines

International Journal of Cancer

Volumn 47, Issue 3, 1991, Pages 401-407

  Tsai, Chun‐Ming ^a   Gazdar, Adi F ^b   Perng, Reury‐Perng ^a   Kramer, Barnett S ^b,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; METHOTREXATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG COMBINATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; TUMOR CELL LINE;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMAN; LUNG NEOPLASMS; METHOTREXATE; MICROCOMPUTERS; MOLECULAR CONFORMATION; NEOPLASMS; SOFTWARE; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0026088842     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910470316     Document Type: Article

References (42)

1. Sequential methotrexate and 5‐fluorouracil in the primary treatment of metastatic colorectal carcinoma
2. Synergism of methotrexate with imuran and with 5‐fluorouracil and their effects on hemolysin plaque‐forming cell production in the mouse
3. Schedule‐dependent cytotoxicity of methotrexate and 5‐fluorouracil in human colon and breast tumor cell lines
4. Optimal scheduling of methotrexate and 5‐fluorouracil in human breast cancer
5. Synergy, additivism and antagonism in immunosuppression: a critical review
6. What is synergy?
7. Sequential methotrexate and 5‐fluorouracil: mechanisms of synergy
8. Schedule‐dependent anti‐tumor effects of methotrexate and 5‐fluorouracil
9. A basis for fluoropyrimidine‐induced antagonism to methotrexate in Ehrlich ascites tumor cells in vitro
10. Growth of cell lines and clinical specimens of human non‐small‐cell lung cancer in a serum‐free defined medium
11. Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not anti‐tumor effects in patients with squamous‐cell head and neck cancer: results from a randomized trial
12. Survival results from a phase‐III study of simultaneous versus 1‐hour sequential methotrexate‐5‐fluorouracil chemotherapy in head and neck cancer
13. Enhanced 5‐fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism
14. Evaluation of a tetrazolium‐based semi‐automated colorimetric assay: assessment of chemosensitivity testing
15. Sequential MTX and 5‐FU: advance or myth?
16. Combination therapy with methotrexate and 5‐fluorouracil: a prospective randomized clinical trial of order of administration
17. Selective alteration of immunocompetence with methotrexate and 5‐fluorouracil
18. A randomized trial of fluorouracil and folinic acid in patients with colorectal carcinoma
19. Growth of cell lines and clinical specimens of human non‐small‐cell lung cancer in a serum‐free defined medium (Letter to the editor)
20. Sequential methotrexate, 5‐fluorouracil, and calcium leucovorin in corectal carcinoma
21. Prolong survival in mammary‐tumor‐bearing mice treated with a regimen of methotrexate, leucovorin, and 5‐fluorouracil
22. Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity
23. Sequential methotrexate plus 5‐FU in advanced breast and colorectal cancers: a phase‐II study
24. Sequential therapy with methotrexate and 5‐fluorouracil in the treatment of advanced colorectal carcinoma
25. The increased cytotoxicity in colon adenocarcinoma of methotrexate‐5‐fluorouracil is not associated with increased induction of lesions in DNA by 5‐fluorouracil
26. Chemotherapy of advanced colorectal cancer: a randomized trial of sequential methotrexate and 5‐fluorouracil
27. Chemotherapy of advanced head and neck cancer: a randomized trial of the order of administration of sequential methotrexate and 5‐fluorouracil
28. Sequential methotrexate, 5‐fluorouracil and leucovorin in metastatic colorectal cancer: a controlled comparison of two intervals between drug administration
29. An overview of thymidine
30. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays
31. A phase‐II study of sequential methotrexate and fluorouracil in advanced colorectal cancer
32. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium‐based colorimetric assay
33. Characteristics of cell lines established from human colorectal carcinomas
34. A prospective randomized trial of 5‐fluorouracil versus 5‐fluorouracil and high‐dose leucovorin versus 5‐fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma
35. Critical modulation by thymidine and hypoxantine of sequential mefhotrexate‐5‐fluorouracil synergism in murine L1210 cells
36. Exploitable mechanisms in combined radiotherapy‐chemotherapy: the concept of additivity
37. Combination chemotherapy: the interaction of methotrexate and 5‐fluorouracil
38. Lack of in vitro synergy between etoposide and cis‐diammine‐dichloroplatinum (II)
39. Cytotoxicity of 5‐fluoro‐2′‐deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate
40. Sequential methotrexate and 5‐FU in the treatment of colorectal cancer
41. Prevention of anti‐tumor effect of 5‐fluorouracil by hypoxanthine